PolyPid (PYPD) AI Stock Analysis

• Market Cap: $67.56M
• Dividend Yield: N/A
• Average Volume (3M): 72.46K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.58
• Revenue Growth: N/A
• EPS Growth: 61.23%
• Country: US
• Employees: 57
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.41
• Shares Outstanding: 15,897,201
• 10 Day Avg. Volume: 44,210
• 30 Day Avg. Volume: 72,461
• PEG Ratio: 0.04
• Price to Book (P/B): 6.47
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.59
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -1.22
• 1Y Price Target: $11.67
• Price Target Upside: 176.54% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): -1.32
• Revenue Forecast (FY): $850.00K

• Rating: 56 Neutral
• Price Target: $4.50 ▲(6.64% Upside)
• Action: Reiterated Date: 12/30/25
• Date: Action: Reiterated 12/30/25

The score is held back primarily by weak financial fundamentals (no revenue, continued losses/cash burn, and financing risk). Offsetting this is a favorable earnings-call outlook with clear regulatory timelines and commercial readiness progress, while technicals show an uptrend but appear overbought. Valuation is difficult to anchor given negative earnings and no dividend.

Positive Factors

Clinical Trial Progress

The positive recommendation from the DSMB indicates promising efficacy signals for D-PLEX100, enhancing its potential for regulatory approval and commercialization.

Financing and Cash Runway

The successful financing extends operational runway, providing financial stability to advance clinical trials and regulatory activities.

Market Potential for D-PLEX100

The large addressable market for D-PLEX100 in surgical procedures offers significant revenue potential upon successful commercialization and approval.

Negative Factors

Consistent Financial Losses

Ongoing financial losses highlight challenges in achieving profitability, which could impact long-term sustainability and require continued external financing.

Negative Equity

Negative equity suggests solvency issues, limiting financial flexibility and increasing reliance on external funding to support operations.

Increased R&D Expenses

Rising R&D costs, while necessary for product development, exacerbate financial strain and may delay the path to profitability if not managed effectively.

PolyPid Business Overview & Revenue Model

Company Description

PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

How the Company Makes Money

PolyPid generates revenue primarily through the development and commercialization of its proprietary PLEX technology, which facilitates the extended release of drugs at surgical sites. The company's revenue model is focused on advancing its product pipeline through clinical trials towards regulatory approval and subsequent commercialization. Revenue streams include potential sales of its lead product candidate D-PLEX100 upon approval, as well as future licensing and partnership deals with other pharmaceutical companies. These partnerships may involve co-development, marketing, and distribution agreements, enhancing PolyPid's market reach and revenue potential.

PolyPid Financial Statement Overview

Summary

Early-stage, pre-revenue profile with ongoing operating losses and cash burn. 2024 net loss widened again and operating/free cash flow stayed deeply negative, while leverage is meaningful versus equity (including prior negative equity), raising ongoing funding risk despite some improvement versus 2021–2022.

Income Statement

PolyPid remains a pre-revenue biotech (revenue is $0 across all shown years), so operating losses are the defining feature of the income statement. Losses improved meaningfully from 2022 to 2023 (net loss narrowed from ~$39.5M to ~$23.9M), but widened again in 2024 (net loss ~-$29.0M). Overall, the trajectory shows ongoing and volatile R&D/operating burn with no revenue base yet to absorb fixed costs.

Balance Sheet

The balance sheet shows elevated leverage and weakening capitalization versus earlier years. Debt is ~$9.6M in 2024 against equity of ~$7.7M (debt-to-equity ~1.25x), and equity was negative in 2023, highlighting prior balance-sheet stress and reliance on external funding. Total assets rebounded in 2024 (~$25.2M) from 2023 (~$15.4M), but persistent losses continue to pressure equity and increase financing risk.

Cash Flow

Cash generation is consistently negative, with operating cash flow of about -$22.0M in 2024 (worse than -$17.2M in 2023), indicating continued cash burn. Free cash flow remains deeply negative (about -$22.0M in 2024), though burn improved substantially versus 2021–2022. A modest positive is that free cash flow has generally tracked net loss closely (free cash flow to net income near 1.0x), suggesting losses are largely reflected in cash usage rather than being masked by large non-cash benefits.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	-1.72M	-1.12M
EBITDA	-31.86M	-26.41M	-21.05M	-36.37M	-41.48M
Net Income	-34.17M	-29.02M	-23.86M	-39.52M	-40.71M
Balance Sheet
Total Assets	22.31M	25.22M	15.37M	25.97M	44.23M
Cash, Cash Equivalents and Short-Term Investments	12.93M	15.64M	5.61M	12.59M	32.20M
Total Debt	2.80M	9.62M	11.78M	13.73M	0.00
Total Liabilities	11.33M	17.54M	17.47M	20.14M	8.28M
Stockholders Equity	10.97M	7.68M	-2.10M	5.83M	35.96M
Cash Flow
Free Cash Flow	0.00	-22.04M	-17.43M	-36.08M	-35.38M
Operating Cash Flow	0.00	-21.96M	-17.24M	-34.32M	-32.39M
Investing Cash Flow	0.00	-330.00K	3.80M	16.57M	36.90M
Financing Cash Flow	0.00	32.42M	9.98M	16.43M	1.03M

PolyPid Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 4.22
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PYPD, the sentiment is Neutral. The current price of 4.22 is below the 20-day moving average (MA) of 4.44, below the 50-day MA of 4.41, and above the 200-day MA of 3.70, indicating a neutral trend. The MACD of -0.07 indicates Positive momentum. The RSI at 43.57 is Neutral, neither overbought nor oversold. The STOCH value of 37.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PYPD.

PolyPid Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PYPD	56 Neutral	$67.56M	-1.90	-390.53%	―	―	61.23%
APLM	52 Neutral	$22.16M	-0.74	-380.13%	―	―	54.41%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SABS	50 Neutral	$178.05M	-1.27	-21.16%	―	-92.42%	62.37%
CTXR	45 Neutral	$16.78M	-0.26	-54.40%	―	―	18.73%

PolyPid Corporate Events

PolyPid Calls February 2026 Extraordinary Meeting to Approve Board Chair Compensation

On December 31, 2025, PolyPid Ltd. reported that it has convened an Extraordinary General Meeting of Shareholders to be held on February 4, 2026, at its Petach Tikva headquarters, with a single agenda item: approval of the compensation terms of Ms. Brooke Story, chair of the company’s board of directors. Shareholders of record at the close of business on January 5, 2026, will be entitled to receive notice and vote, either in person or by proxy, with the board recommending support for the proposed resolution, underscoring the company’s focus on formalizing board leadership compensation as part of its ongoing corporate governance framework.

The most recent analyst rating on (PYPD) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on PolyPid stock, see the PYPD Stock Forecast page.

PolyPid Appoints Brooke Story as Chairman Amid Strategic Growth

PolyPid Ltd. announced the appointment of Brooke Story as Chairman of the Board of Directors, effective December 11, 2025. With over 25 years of MedTech leadership experience, including senior roles at Becton, Dickinson and Company and Medtronic PLC, Story’s expertise in surgical markets and corporate strategy is expected to enhance PolyPid’s strategic, commercial, and transaction capabilities. This appointment comes at a crucial time as PolyPid prepares for the New Drug Application submission of D-PLEX100, potentially transforming its clinical success into commercial reality and creating significant enterprise value.

The most recent analyst rating on (PYPD) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on PolyPid stock, see the PYPD Stock Forecast page.

PolyPid Gains FDA Support for D-PLEX100 NDA Submission

On December 3, 2025, PolyPid announced receiving positive feedback from the FDA regarding its pre-NDA meeting for D-PLEX100, a product designed to prevent surgical site infections. The FDA’s agreement on the adequacy of PolyPid’s clinical data package, including successful Phase 3 trial results, supports the company’s plan to submit a rolling NDA in early 2026. This development validates PolyPid’s regulatory strategy and positions the company to potentially bring a transformative treatment to market, enhancing its standing in the biopharmaceutical industry.

The most recent analyst rating on (PYPD) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on PolyPid stock, see the PYPD Stock Forecast page.

PolyPid Expands Share Offering to Strengthen Financial Position

On November 26, 2025, PolyPid Ltd. announced an increase in the maximum aggregate offering price of its ordinary shares from $8,250,000 to $15,000,000 under its Sales Agreement with Oppenheimer & Co. Inc. This strategic financial move is aimed at bolstering the company’s capital base, potentially enhancing its market position and providing additional resources to advance its business objectives.

The most recent analyst rating on (PYPD) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on PolyPid stock, see the PYPD Stock Forecast page.

PolyPid Advances D-PLEX₁₀₀ Towards FDA Submission and Commercial Readiness

PolyPid Ltd. announced its third-quarter 2025 financial results and provided a corporate update, highlighting significant advancements in its regulatory strategy and commercial readiness for D-PLEX₁₀₀. The company is preparing for a pre-NDA meeting with the FDA in December and aims to submit an NDA in early 2026. Strategic partnership discussions in the U.S. have progressed following positive Phase 3 trial results. The company also completed a successful GMP inspection by the Israeli Ministry of Health, marking a key milestone towards commercial manufacturing readiness. Financially, PolyPid reported a net loss of $7.5 million for the quarter but reduced its long-term debt significantly, with cash reserves expected to support operations into 2026.

The most recent analyst rating on (PYPD) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on PolyPid stock, see the PYPD Stock Forecast page.